TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39645388

Group type: EXPERIMENTAL
Intervention: Community walking and home-based circuit training programme
Number of subjects: 34
Study: 39647171

Group type: EXPERIMENTAL
Intervention: BNC210
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 39647248

Group type: EXPERIMENTAL
Intervention: P3 intervention (text-messages linking to animated videos)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (patient education webpages)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: P3 fathers
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Parents who viewed the video on fathers' rights
Number of subjects: 104
Study: 39647263

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet
Number of subjects: 30
Study: 39647494

Group type: EXPERIMENTAL
Intervention: MenABCWY (two doses at months 0 and 6)
Number of subjects: 3651

Group type: EXPERIMENTAL
Intervention: MenABCWY
Number of subjects: 3651

Group type: COMPARATOR
Intervention: 4CMenB (two doses at months 0 and 6)
Number of subjects: 3651

Group type: COMPARATOR
Intervention: MenACWY-CRM (one dose at month 0)
Number of subjects: 3651
Study: 39647798

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (standard-of-care antibiotics)
Number of subjects: 0
Study: 39647797

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneously once daily for 10 days
Number of subjects: 992
Study: 39647999

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bendamustine and Rituximab
Number of subjects: 0
Study: 39648069

Group type: EXPERIMENTAL
Intervention: Class II occlusion group (study group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (neutral occlusion)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Overall group of participants
Number of subjects: 37
Study: 39648079

Group type: EXPERIMENTAL
Intervention: Chef-ID intervention (12-week program including weekly group sessions for cooking skills, nutrition education, and exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chef-ID intervention
Number of subjects: 0
Study: 39648196

Group type: EXPERIMENTAL
Intervention: Hernia Blocking System (HBS) implanted after limited discectomy
Number of subjects: 30
Study: 39648217

Group type: EXPERIMENTAL
Intervention: Anlotinib plus chemotherapy
Number of subjects: 91
Study: 39648226

Group type: EXPERIMENTAL
Intervention: pyrotinib
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: metabolic pathway-related gene mutations
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: decreased or achieved early clearance of ctDNA after the initial two treatment cycles
Number of subjects: 1071

Group type: COMPARATOR
Intervention: chemotherapy, endocrine therapy, or CDK4/6 inhibitor therapy
Number of subjects: 1071
Study: 39648235

Group type: EXPERIMENTAL
Intervention: Waiting for spinal arthrodesis
Number of subjects: 15
Study: 39648279

Group type: EXPERIMENTAL
Intervention: Therakos CELLEX
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amicus ECP system
Number of subjects: 20
Study: 39648559

Group type: EXPERIMENTAL
Intervention: BLV 2 mg
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: BLV 10 mg
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: pegylated interferon-alfa
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control (delayed treatment group)
Number of subjects: 269
Study: 39648614

Group type: EXPERIMENTAL
Intervention: Islatravir 60 mg single oral dose
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard methadone therapy
Number of subjects: 14
Study: 39648617

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39648629

Group type: EXPERIMENTAL
Intervention: Atogepant
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 39648796

Group type: EXPERIMENTAL
Intervention: Daily chicken egg intake for 6 months
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Baseline IGF-1
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Baseline FGF21
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Baseline I-FABP
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Baseline soluble CD14
Number of subjects: 500
Study: 39648851

Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based motor imagery (Tele-MI) training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Telerehabilitation-based physiotherapy program (Tele-PTP)
Number of subjects: 23
Study: 39648884

Group type: EXPERIMENTAL
Intervention: Amyloid PET positive patients
Number of subjects: 91

Group type: COMPARATOR
Intervention: Amyloid PET negative patients
Number of subjects: 91
Study: 39648888

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 1643
Study: 39648909

Group type: EXPERIMENTAL
Intervention: Nerinetide
Number of subjects: 446

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 446
Study: 39649024

Group type: EXPERIMENTAL
Intervention: eHealth-based behavior intervention program
Number of subjects: 58
Study: 39649127

Group type: EXPERIMENTAL
Intervention: KONTAKT™ Social Skills Toolbox Group Program (16 sessions, 60 minutes each)
Number of subjects: 15
Study: 39649135

Group type: EXPERIMENTAL
Intervention: CD40.HIVRI.Env (0.3, 1.0, or 3.0 mg) alone or co-administered with DNA-HIV-PT123
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 39649157

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) knowledge and acceptability among fishermen
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) distribution by promoters
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) discussions
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Promoter model for HIVST
Number of subjects: 65
Study: 39649162

Group type: EXPERIMENTAL
Intervention: Collaborative care model (CoCM)
Number of subjects: 10
Study: 39649163

Group type: EXPERIMENTAL
Intervention: Active implementation of CV Toolkit
Number of subjects: 6009
Study: 39649172

Group type: EXPERIMENTAL
Intervention: Library-facilitated telehealth intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition (in-person or phone follow-up)
Number of subjects: 40
Study: 39649400

Group type: EXPERIMENTAL
Intervention: Stage 1 formula providing 3.6 g intact protein/100 kcal consumed until reaching 1,800 g, followed by Stage 2 formula with 2.8 g/100 kcal protein for 30 days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage 1 formula
Number of subjects: 0
Study: 39649618

Group type: EXPERIMENTAL
Intervention: EHR sample (n=1817)
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: Survey sample (n=996)
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: Referral cohort
Number of subjects: 2767
Study: 39649709

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 200

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 200
Study: 39649724

Group type: EXPERIMENTAL
Intervention: avapritinib
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: midostaurin
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: decitabine-cedazuridine
Number of subjects: 1
Study: 39649816

Group type: EXPERIMENTAL
Intervention: Shockwave Coronary intravascular lithotripsy (IVL) system
Number of subjects: 400
Study: 39651299

Group type: EXPERIMENTAL
Intervention: Patient-derived xenograft (PDX) models from chemosensitive tumors
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Patient-derived xenograft (PDX) models from chemoresistant tumors
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Longitudinal PDX models
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Overall PDX biobank
Number of subjects: 75
Study: 39651334

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham TENS treatment
Number of subjects: 46
Study: 39651546

Group type: EXPERIMENTAL
Intervention: Black soymilk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pork
Number of subjects: 0
Study: 39651791

Group type: EXPERIMENTAL
Intervention: Blinatumomab plus chemotherapy
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Blinatumomab plus chemotherapy (average relapse risk)
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Chemotherapy alone (average relapse risk)
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Blinatumomab plus chemotherapy (high relapse risk)
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Chemotherapy alone (high relapse risk)
Number of subjects: 1440
Study: 39651882

Group type: COMPARATOR
Intervention: BRII-693 (10-400 mg single dose)
Number of subjects: 104

Group type: COMPARATOR
Intervention: BRII-693 (100-200 mg 7-day repeat dose)
Number of subjects: 104

Group type: COMPARATOR
Intervention: BRII-693 (150 mg 14-day repeat dose)
Number of subjects: 104
Study: 39651891

Group type: EXPERIMENTAL
Intervention: Electrocorticography monitoring for spreading depolarization (SD) events
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 39651910

Group type: EXPERIMENTAL
Intervention: Combination drug regimens containing bedaquiline
Number of subjects: 0
Study: 39651931

Group type: EXPERIMENTAL
Intervention: 23ME-00610 (2 mg initially, then 1400 mg Q3W)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 23ME-00610 (doses ≥ 60 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 23ME-00610
Number of subjects: 28
Study: 39652156

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab monotherapy
Number of subjects: 19
Study: 39652198

Group type: EXPERIMENTAL
Intervention: Savolitinib
Number of subjects: 5
Study: 39652211

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at acupoints LI4, SJ6, ST36, and ST37, administered twice daily from the day of surgery until the fourth day after the operation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sham-electroacupuncture (SA), administered twice daily from the day of surgery until the fourth day after the operation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group following a standardized Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 300
Study: 39652324

Group type: EXPERIMENTAL
Intervention: Neurological Pupil Index (NPi) measurements
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Invasive intracranial pressure (ICP) monitoring
Number of subjects: 318
Study: 39652340

Group type: EXPERIMENTAL
Intervention: Discontinue first-line DMT
Number of subjects: 89

Group type: COMPARATOR
Intervention: Continue first-line DMT
Number of subjects: 89
Study: 39652356

Group type: EXPERIMENTAL
Intervention: Integrated Pain Team (IPT)
Number of subjects: 820

Group type: COMPARATOR
Intervention: Pharmacist Collaborative Management (PCM)
Number of subjects: 820
Study: 39652561

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) regimen of 10-h eating window for 6 months
Number of subjects: 32
Study: 39652594

Group type: EXPERIMENTAL
Intervention: Isa-RVd
Number of subjects: 662

Group type: COMPARATOR
Intervention: RVd
Number of subjects: 662
Study: 39652675

Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 390

Group type: COMPARATOR
Intervention: Active Monitoring
Number of subjects: 390
Study: 39652807

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 451
Study: 39652823

Group type: EXPERIMENTAL
Intervention: Venetoclax plus Azacitidine (RP2D: Venetoclax 400 mg for 14 days/28-day cycle, Azacitidine 75 mg/m2 for 7 days/28-day cycle)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Venetoclax plus Azacitidine
Number of subjects: 107
Study: 39652826

Group type: EXPERIMENTAL
Intervention: Intravenous daratumumab 16 mg/kg (Long intense)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intravenous daratumumab 16 mg/kg (Intermediate)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intravenous daratumumab 16 mg/kg (Short intense)
Number of subjects: 123
Study: 39652859

Group type: EXPERIMENTAL
Intervention: Web-Based Toolkit for Resilient Life Beyond Pain and Substance Use (Web-TIRELESS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Minimally enhanced usual care
Number of subjects: 50
Study: 39652863

Group type: EXPERIMENTAL
Intervention: Healthy Living for Reduced Anxiety (psychoeducation about lifestyle changes)
Number of subjects: 56

Group type: COMPARATOR
Intervention: BREATHE (breathing and progressive relaxation)
Number of subjects: 56
Study: 39652866

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) exercises for breathing and physical exercises
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual physiotherapy (control group) consisting of protocolized breathing exercises (8 times daily for 10 minutes) and physical exercises (2 times daily for 10 minutes)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) exercises
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual physiotherapy (control group)
Number of subjects: 27
Study: 39653044

Group type: EXPERIMENTAL
Intervention: Tezepelumab 420 mg subcutaneously every 4 weeks for up to 52 weeks
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo subcutaneously every 4 weeks for up to 52 weeks
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Tezepelumab in patients with baseline BEC < 150 cells/μL
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo in patients with baseline BEC < 150 cells/μL
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Tezepelumab in patients with baseline BEC 150 to < 300 cells/μL
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo in patients with baseline BEC 150 to < 300 cells/μL
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Tezepelumab in patients with baseline BEC ≥ 300 cells/μL
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo in patients with baseline BEC ≥ 300 cells/μL
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study: 39653116

Group type: EXPERIMENTAL
Intervention: HBI0101 anti-BCMA CART therapy, infused with 800 × 10 after lymphodepletion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: HBI0101 anti-BCMA CART therapy
Number of subjects: 16
Study: 39653325

Group type: EXPERIMENTAL
Intervention: Mavacamten treatment
Number of subjects: 0
Study: 39653554

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 inhibitors in combination with chemotherapy
Number of subjects: 30
Study: 39653558

Group type: EXPERIMENTAL
Intervention: KindMap experimental group (KindMap-EG; with immediate access to the web app)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study: 39653557

Group type: EXPERIMENTAL
Intervention: Intensive patient and caregiver-oriented transition support provided by a multidisciplinary transition team for 2 years.
Number of subjects: 154

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 154
Study: 39653573

Group type: EXPERIMENTAL
Intervention: Tailor-made nutrition therapy consisting of oral nutritional supplements and supplementary parenteral nutrition for 10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard nutrition with dietary advice
Number of subjects: 60
Study: 39653674

Group type: EXPERIMENTAL
Intervention: Bioactive injectable resin composite
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nanohybrid resin composite
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 18
Study: 39653676

Group type: EXPERIMENTAL
Intervention: Oral tenofovir-based PrEP with point-of-care urine tenofovir testing and adherence counselling
Number of subjects: 3087
Study: 39653817

Group type: EXPERIMENTAL
Intervention: PET imaging with approximately 150 MBq of [
Number of subjects: 11
Study: 39653946

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy or targeted axillary dissection with regional nodal irradiation
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: Non-pathologic complete response (non-pCR) in the breast
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: cT3-4
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: Nonluminal pathology
Number of subjects: 2407
Study: 39654273

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (alteplase 0.90 mg/kg or conservative management)
Number of subjects: 0
Study: 39654280

Group type: EXPERIMENTAL
Intervention: Wearable alcohol biosensor monitors (ABM)
Number of subjects: 23
Study: 39654356

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A, administered every 12 weeks, 155 units total
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo, administered every 12 weeks
Number of subjects: 200
Study: 39654362

Group type: EXPERIMENTAL
Intervention: Carfilzomib with lenalidomide and dexamethasone (KRd)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Carfilzomib with dexamethasone only (Kd)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Carfilzomib with daratumumab and dexamethasone (KdD)
Number of subjects: 359
Study: 39654449

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39654480

Group type: EXPERIMENTAL
Intervention: Comprehensive clinical examination including medical history, radiographic tests, and physical examination testing
Number of subjects: 364

Group type: COMPARATOR
Intervention: Medical history only
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Medical history plus radiographic testing
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Medical history, radiographic testing, and physical examination testing
Number of subjects: 364
Study: 39654551

Group type: EXPERIMENTAL
Intervention: Awake prone positioning (APP)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 93
Study: 39654645

Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation (PNS)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Combination of PNS and Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Neurostimulation (PNS and SCS)
Number of subjects: 2
Study: 39654971

Group type: EXPERIMENTAL
Intervention: Nutrition education and counseling (NEC) intervention
Number of subjects: 311

Group type: COMPARATOR
Intervention: Standard antenatal health education (Control)
Number of subjects: 311
Study: 39655042

Group type: EXPERIMENTAL
Intervention: Community paramedicine (CP) care
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 39655060

Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT) total score
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Single items of the CAT
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Exacerbation risk
Number of subjects: 2509
Study: 39655088

Group type: EXPERIMENTAL
Intervention: Basivertebral nerve ablation (BVNA) using the INTRACEPT® device
Number of subjects: 35
Study: 39655211

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Groups (DBT-SG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 39655786

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (mandatory transfusion at hemoglobin level ≤10 g/dL)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (optional transfusion at hemoglobin level ≤8 g/dL)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 742

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 742
Study: 39655790

Group type: EXPERIMENTAL
Intervention: CD68-ET3-LV-transduced autologous CD34+ HSCs at doses of 5.0×10
Number of subjects: 5
Study: 39656268

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (losartan and irbesartan)
Number of subjects: 2661
Study: 39656317

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) program for 12 weeks
Number of subjects: 69
Study: 39656429

Group type: EXPERIMENTAL
Intervention: PD-L1 positivity (IC ≥ 1% and/or CPS ≥ 1)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Intermediate PD-L1 expression (IC > 0%, < 1; CPS > 0, < 1)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Low TILs (< 30%) and PD-L1 (IC < 1%; CPS < 1)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: PD-L1 positive tumors
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: PD-L1-zero tumors
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: PD-L1-intermediate tumors
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Any PD-L1 IHC expression (< 1)
Number of subjects: 237
Study: 39656458

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 12265

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 12265
Study: 39656459

Group type: EXPERIMENTAL
Intervention: Layperson-delivered empathetic engagement via telephone for 6 months
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Layperson-delivered empathetic engagement via telephone for 6 months (subgroup with PHQ-9 score ≥5)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual care (subgroup with PHQ-9 score ≥5)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Layperson-delivered empathetic engagement via telephone for 6 months (subgroup with PHQ-9 score <5)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual care (subgroup with PHQ-9 score <5)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Layperson-delivered empathetic engagement via telephone
Number of subjects: 260
Study: 39656510

Group type: EXPERIMENTAL
Intervention: Mobile step-tracking app intervention (EG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study: 39656600

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg, intravenously) on Day 1 combined with XELOX (oxaliplatin at 130 mg/m2 and capecitabine)
Number of subjects: 0